Having met management multiple times, I always found Keating in particular level headed and focused. They certainly have been blindsided by these results and clearly misunderstood the complexity in the US and how to design a clinical study.
They took the SP from 2c to 55c now its heading back to square one - marketing praise has to be given but its all counted for nothing. I sincerely hope they turn this around.
Many ex-holders will still be in shock. This is part and parcel of the market.
RAP Price at posting:
8.8¢ Sentiment: None Disclosure: Not Held
